Synthesis of [4-(2-hydroxyphenyl)thiazol-2-yl]methanones as potential bioisosteres of salicylidene acylhydrazides

Article abstract of DOI:10.3390/molecules15096019

A focused library of [4-(2-hydroxyphenyl)thiazol-2-yl]methanones was prepared in a four-step synthesis with the aim to obtain potent inhibitors of type III secretion in Gram-negative bacteria. The compounds are potential bioisosteres of salicylidene acylhydrazides that are a known class of type III secretion inhibitors.

Full text of DOI:10.3390/molecules15096019

Molecules 2010, 15, 6019-6034; doi:10.3390/molecules15096019
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Synthesis of [4-(2-Hydroxyphenyl)thiazol-2-yl]methanones as
Potential Bioisosteres of Salicylidene Acylhydrazides
J. Mikael Hillgren, Markus K. Dahlgren, Tam M. To and Mikael Elofsson *
Department of Chemistry, Umeå University, SE-90187, Umeå, Sweden
* Author to whom correspondence should be addressed; E-Mail: mikael.elofsson@chem.umu.se;
Tel.: +46-90-786-9328.
Received: 6 July 2010; in revised form: 26 August 2010 / Accepted: 30 August 2010 /
Published: 31 August 2010
Abstract: A focused library of [4-(2-hydroxyphenyl)thiazol-2-yl]methanones was
prepared in a four-step synthesis with the aim to obtain potent inhibitors of type III
secretion in Gram-negative bacteria. The compounds are potential bioisosteres of
salicylidene acylhydrazides that are a known class of type III secretion inhibitors.
Keywords: type III secretion; Suzuki coupling; Grignard addition
1. Introduction
Today it is clear that resistant bacteria constitute a threat to human health and development of new
antibacterial drugs is critical to extend the successful antibiotic era. Several Gram-negative pathogens
including Yersinia spp., Shigella spp., Chlamydia spp., Salmonella spp., Pseudomonas aeruginosa, and
enteropathogenic and enterohaemorrhagic Escherichia coli use type III secretion (T3S) of bacterial
toxins to evade the human immune system and establish disease [1]. Without T3S the bacteria are
essentially harmless and small molecules that inhibit this important protein export machinery therefore
have the potential to be developed into novel antibacterial agents [2-4]. Importantly such molecules
would not target bacterial growth in a non-selective manner and thereby spare the endogenous
microflora. T3S inhibitors thus disarm the pathogen and allow the host immune system to clear the
infection and it is expected that this mode of action will result in reduced pressure for development of
resistance. This mode of action is in contrast to current antibiotics that either are bacteriostatic or
bacteriocidal without distinction between pathogenic and benign endogenous bacteria.

Molecules 2010, 15
6020
Salicylidene acylhydrazides (Figure 1a) constitute a class of compounds that blocks T3S in Y.
pseudotuberculosis, Shigella flexneri, enterohaemorrhagic E. coli, Chlamydia spp., and Salmonella
spp. [5-13]. Their activity against multiple species indicates that T3S inhibitors potentially can be
developed into novel antibacterial drugs. Activity in vivo has been demonstrated [11,14] and in a
recent study quantitative structure-activity relationship models indicated that the pKa of the salicylic
aldehyde phenol part and atomic partial charges of the aromatic carbon atoms of the salicylic phenyl
ring are important for T3S inhibition in Y. pseudotuberculosis [15]. Salicylidene acylhydrazides can
chelate iron and it cannot be excluded that this property influences the observed T3S inhibition [9].
However, the salicylidene acylhydrazide T3S inhibitors generally suffer from some drawbacks
including acid sensitivity, limited solubility and modest potency. One strategy to reduce the acid
sensitivity and possibly increase the potency of the compounds is to replace the methylidenehydrazide
part (Figure 1b) with another functional group. In a recent article 2-(2-aminopyrimidine)-2,2-
difluoroethanols were prepared in a scaffold hopping approach to obtain possible bioisosteres [16].
This paper describes the synthesis of a library of [4-(2-hydroxyphenyl)thiazol-2-yl]methanones and the
biological evaluation of this library in whole-cell Y. pseudotuberculosis assays.
Figure 1. a) General structure of salicylidene acylhydrazides. b) The methylidenehydrazide
linker. c) The commercially available thiazole that was identified as a possible
methylidenehydrazide replacement. d) Substituted thiazoles.
HO
HO
O
O
R2
Br
N
O
R2
R1
N
R2
a)
N
d)
b)
N
c)
N
H
R1
N
H
H
S
R1
S
2. Results and Discussion
Through commercial sources, building blocks that could mimic the methylidene hydrazide part and
allow introduction of the acyl and phenol moieties were sought. A thiazole (Figure 1c) was identified
as a plausible replacement of the three-atom linker of the central fragment. Interestingly, such
substituted thiazoles (Figure 1d) display high structural similarity to the partially reduced thiazole
skeleton in the natural product yersinabactin that is an iron chelating siderophore produced by several
microorganisms, including Yersinia spp. [17].
The thiazole compounds could be synthesized in four steps, using well-established reactions. The
different building blocks and substituent patterns were selected based on structural information
available for active salicylidene acylhydrazides [5,15]. Suzuki coupling under standard conditions
between commercially available 4-bromothiazol-2-yl carboxaldehyde and four different boronic acids
gave biaryl compounds 1a-d in moderate (57-67%) yields (Scheme 1). Further functionalization of the
molecular backbone was performed by addition of aryl Grignard reagents to the aldehyde moiety of
1a-d to furnish alcohols 2a-i (Scheme 1) in good yields (67-89%), with the exception of 2c and 2f that
were isolated in about 40% yield. This was followed by oxidation with Dess-Martin periodinane to
give ketones 3a-i (Scheme 1) in good to excellent yields (52-100%). The oxidation-sensitive
thiophenyl derivative 3h could however only be isolated in 27% yield. Demethylation of 3a-i with

Molecules 2010, 15
6021
BBr3 furnished the salicylidene acylhydrazide mimics 4a-i in low or moderate yields (typically less
than 40%; Scheme 1). Ketone 3i gave only 4i under these conditions, while the fully deprotected
analogue 4j was obtained using an alternative procedure employing dodecylthiolate in 1-
methylpyrrolidin-2-one [18]. Substrate 3c was deprotected using cerium(III) ammonium nitrate
followed by Na2S2O3 in an attempt to avoid supposed substrate decomposition under the harsh reaction
conditions associated with the other two methods, resulting in the hydroquinone 4c in an acceptable
yield (41%). The low yields in the last step could at least in part be explained by isolation problems.
Considerable loss of material was experienced following purification by both reversed and normal
phase chromatography. Nevertheless, enough material of each analog was produced for biological
testing. Purity of the compounds was assessed using HPLC and 1H-NMR and determined to be at least
90% for the intermediates (1a-d, 2a-i, and 3a-i) and at least 95% for the final products (4a-j).
All target compounds 4a-j and intermediates 2a-i and 3a-i were tested for their ability to selectively
inhibit T3S using a luciferase reporter-gene assay and an assay monitoring phosphatase activity of the
secreted effector protein YopH as described previously [19]. None of the compounds showed
inhibitory activity in the reporter-gene assay higher than the previously set threshold of 40% at 50 μM
concentration and the YopH assay confirmed lack of activity [19].
Scheme 1. Synthesis of the thiazoles.
a) Method: 1. CAN, MeCN/H2O, r.t., 1 h; 2. Na2S2O3, 1,4-dioxane/H2O, r.t., 2 h. b) Method:
C12H25SNa, NMP, 140 ºC microwave irr., 15 min.

Molecules 2010, 15
6022
3. Experimental
3.1. General Chemistry
Chemicals were purchased from Sigma/Aldrich Chemical Co. and used as received unless stated
otherwise. All experiments were conducted under a nitrogen atmosphere, in dried glassware, using
anhydrous solvents unless stated otherwise. Microwave-heated reactions were performed at a fixed
temperature using variable power in EmrysTM process vials (5 mL) using a SmithCreatorTM microwave
instrument from Biotage. Reagent grade dichloromethane and THF were distilled from CaH2 and
molten potassium, respectively. Light petroleum (b.p. 40-60 ºC) is referred to as petrol.
Low-resolution mass-spectra were recorded on a Waters Micromass ZG 2000 instrument with an
electro spray ion source (ES+ and ES−) and using an XTerra® MS C18 5 μm particle size, 4.6 × 50 mm
column and a water/acetonitrile/0.2% formic acid eluent system. High-resolution mass-spectra were
recorded on a Waters Micromass GCT instrument with an electron impact ion source (EI+), direct inlet
(20-400 deg.), or Bruker micrOTOF II with an electro-spray ion source (ES+). Preparative reversed-
phase HPLC was performed on a Beckman System Gold HPLC with a Supelco Discovery BIO Wide
Pore C18 column, using a water/acetonitrile/0.1% trifluoroacetic acid eluent system with a flow rate of
1
11 mL min-1 and detection at 214 nm. H-NMR and 13C-NMR spectra were recorded at 298 K on
Bruker DRX-360 (1H: 360 MHz; 13C: 90 MHz), DRX-400 (1H: 400 MHz; 13C: 100 MHz) or DRX-500
(1H: 500 MHz; 13C: 125 MHz) spectrometers, with chemical shift values being reported in ppm
relative to residual CHCl3 (7.26 (δH) and 77.16 (δC) ppm), CD3OH (3.31 (δH) and 49.00 (δC) ppm) or
acetone-d5 (2.05 (δH) and 29.84 (δC) ppm) as internal standard. Peak assignments could be established
from complementary HMBC, HSQC and COSY experiments. Infrared spectra were recorded using a
customized Perkin Elmer Spectrum BX FT-IR/ATR spectrophotometer. Melting points were measured
using a Büchi/Dr. Tottoli melting point determination apparatus and are uncorrected.
3.2. Synthesis
3.2.1. General procedure for Suzuki coupling
4-Bromothiazole-2-carboxaldehyde (538 mg, 2.80 mmol), tetrakis(triphenylphosphine)palladium(0)
(485 mg, 0.410 mmol) and caesium carbonate (2.01 g, 6.17 mmol) were dissolved in 1,4-dioxane
(20 mL) and the resulting suspension stirred at r.t. for 5 min. The relevant boronic acid (5.59 mmol)
was added and the resulting mixture refluxed for 30 min. After cooling to ambient temperature brine
(10 mL) was added to the mixture, the layers were separated, and the aqueous layer was extracted with
ethyl acetate (3 × 10 mL). The combined organic layers were dried (Na2SO4) and concentrated, and the
residue was purified by silica gel chromatography (1:9 ethyl acetate-heptanes) to give the
aldehydes 1a-d.
4-(5-Bromo-2-methoxyphenyl)thiazole-2-carboxaldehyde (1a). Obtained on a 2.80 mmol scale as a
pale yellow solid (511 mg, 61%). An analytical sample was recrystallized from chloroform to give pale
yellow needles, m.p. 122.5-126.0 ºC (chloroform); Rf 0.35 (1:1 diethyl ether-petrol); IR νmax/cm-1
1
3329, 3155, 2945, 2844, 1681, 1670; H-NMR δH (400 MHz, CDCl3) 10.06 (s, 1H), 8.43 (d,

Molecules 2010, 15
6023
J = 2.5 Hz, 1H), 8.35 (d, J = 1.2 Hz, 1H), 7.45 (dd, J = 8.8, 2.5 Hz, 1H), 6.91 (d, J = 8.8 Hz, 1H), 3.96
(s, 3H); 13C-NMR δC (100 MHz, CDCl3) 184.1, 164.1, 156.1, 152.9, 132.7, 132.5, 125.2, 124.0, 113.6,
113.1, 56.0; m/z LRMS (ES+) 300.29 (100%, [M(81Br)+H]+), 298.28 (96, [M(79Br)+H]+), 155.16 (85),
149.17 (85).
4-(5-Chloro-2-methoxyphenyl)thiazole-2-carboxaldehyde (1b). Obtained on a 4.00 mmol scale as a
pale yellow solid (579 mg, 57%). An analytical sample was recrystallized from chloroform to give pale
yellow needles, m.p. 125.0-127.0 ºC (chloroform); Rf 0.35 (1:3 ethyl acetate-petrol); IR νmax/cm-1
1
3327, 3158, 2949, 2846, 1680, 1670; H-NMR δH (400 MHz, CDCl3) 10.06 (d, J = 1.3 Hz, 1H), 8.36
(d, J = 1.3 Hz, 1H), 8.29 (d, J = 2.7 Hz, 1H), 7.31 (dd, J = 8.8, 2.7 Hz, 1H), 6.95 (d, J = 8.8 Hz, 1H),
13
3.96 (s, 3H); C-NMR δC (100 MHz, CDCl3) 184.1, 164.1, 155.7, 153.1, 129.8, 129.5, 126.4, 125.2,
123.5, 112.7, 56.0; m/z LRMS (ES+) 256.31 (39%, [M(37Cl)+H]+), 254.30 (100, [M(35Cl)+H]+),
239.25 (41).
4-(2,5-Dimethoxyphenyl)thiazole-2-carboxaldehyde (1c). Obtained on a 0.99 mmol scale as a pale
yellow solid (165 mg, 67%). An analytical sample was recrystallized from chloroform to give pale
yellow needles, m.p. 88.5-89.0 ºC (chloroform); Rf 0.33 (1:3 ethyl acetate-petrol); IR νmax/cm-1 3152,
2994, 2832, 1676; 1H-NMR δH (400 MHz, CDCl3) 10.05 (d, J = 1.3 Hz, 1H), 8.36 (d, J = 1.3 Hz, 1H),
7.87 (d, J = 2.9 Hz, 1H), 6.95 (d, J = 8.9 Hz, 1H), 6.91 (dd, J = 8.9, 2.9 Hz, 1H), 3.90 (s, 3H), 3.86 (s,
13
3H); C-NMR δC (100 MHz, CDCl3) 184.2, 163.8, 154.2, 153.9, 151.4, 124.7, 122.7, 115.7, 114.8,
112.7, 56.1, 56.0; m/z LRMS (ES+) 250.27 (76%, [M+H]+), 235.22 (100), 239.25 (29).
4-(2,4-Dimethoxyphenyl)thiazole-2-carboxaldehyde (1d). Obtained on a 4.00 mmol scale as a pale
yellow solid (605 mg, 61%). An analytical sample was recrystallized from chloroform to give pale
yellow needles, m.p. 110.5-116.0 ºC (chloroform); Rf 0.30 (1:3 ethyl acetate-petrol); IR νmax/cm-1
1
3142, 2836, 1669, 1607, 1575; H-NMR δH (400 MHz, CDCl3) 10.05 (d, J = 1.3 Hz, 1H), 8.21 (d,
J = 8.7 Hz, 1H), 8.19 (d, J = 1.3 Hz, 1H), 6.63 (dd, J = 8.7, 2.4 Hz, 1H), 6.57 (d, J = 2.4 Hz, 1H), 3.93
(s, 3H), 3.86 (s, 3H); 13C-NMR δC (100 MHz, CDCl3) 184.2, 163.7, 161.3, 158.2, 154.6, 131.0, 122.6,
115.5, 105.2, 98.9, 55.63, 55.59; m/z LRMS (ES+) 279.41 (28%), 264.38 (67), 250.34 (100, [M+H]+).
3.2.2. General procedure for Grignard addition
The appropriate aldehyde (1.00 mmol) was dissolved in THF (20 mL) and cooled to 0 ºC.
Arylmagnesium bromide (1-2 M solution in THF; 1.50 mmol) was added dropwise over the course of
5 min. The resulting mixture was stirred for 3 h, followed by further addition of arylmagnesium
bromide (1-2 M solution in THF; 0.500 mmol). After stirring for another 3 h, the mixture was allowed
to warm to r.t. over the course of 14 h. The reaction was quenched by addition of water (20 mL) and
concentrated acetic acid (until pH ≈ 5), the resulting mixture stirred for 10 min, then extracted with
ethyl acetate (3 × 20 mL). The combined organic layers were dried (Na2SO4) and concentrated and the
residue was purified by silica gel chromatography (1:9 ethyl acetate-heptanes) to give the alcohols 2a-i.

Molecules 2010, 15
6024
[4-(5-Bromo-2-methoxyphenyl)thiazol-2-yl](phenyl)methanol (2a). Obtained on a 1.00 mmol scale as a
colourless wax (310 mg, 82%); Rf 0.12 (1:3 ethyl acetate-heptanes); IR νmax/cm-1 3409, 1592, 1573;
1H-NMR δH (400 MHz, CDCl3) 8.38 (d, J = 2.6 Hz, 1H), 7.91 (s, 1H), 7.52 (dd, J = 8.3, 1.6 Hz, 2H),
13
7.42-7.32 (m, 4H), 6.85 (d, 8.8 Hz, 1H), 6.09 (s, 1H), 3.91 (s, 3H); C-NMR δC (100 MHz, CDCl3)
172.1, 155.9, 149.1, 141.4, 132.6, 131.5, 128.9, 128.7, 126.8, 124.7, 119.0, 113.5, 113.0, 74.0, 55.9;
m/z LRMS (ES+) 378.37 (10%, [M(81Br)+H]+), 376.36 (10, [M(79Br)+H]+), 360.36 (100, [M(81Br)–
OH]+), 358.35 (95, [M(79Br)–OH]+).
[4-(5-Chloro-2-methoxyphenyl)thiazol-2-yl](phenyl)methanol (2b). Obtained on a 1.93 mmol scale as
a colourless wax (511 mg, 80%); Rf 0.19 (1:3 ethyl acetate-heptanes); IR νmax/cm-1 3338, 1494, 1476,
1
1452; H-NMR δH (400 MHz, CDCl3) 8.23 (d, J = 2.7 Hz, 1H), 7.91 (s, 1H), 7.52 (dtd, J = 6.9, 1.4,
0.5 Hz, 2H), 7.39 (ddt, J = 7.2, 6.9, 1.5 Hz, 2H), 7.34 (tt, J = 7.2, 1.4 Hz, 1H), 7.23 (dd, J = 8.8,
2.7 Hz, 1H), 6.88 (d, J = 8.8 Hz, 1H), 6.08 (s, 1H), 3.90 (s, 3H); 13C-NMR δC (100 MHz, CDCl3)
172.1, 155.4, 149.2, 141.4, 129.7, 128.8, 128.6, 128.5, 126.8, 126.0, 124.4, 119.0, 112.4, 74.0, 55.9;
m/z LRMS (ES+) 332.34 (10%, [M(35Cl)+H]+), 316.34 (52, [M(37Cl)–OH]+), 314.32 (100,
[M(35Cl)–OH]+).
[4-(2,5-Dimethoxyphenyl)thiazol-2-yl](phenyl)methanol (2c). Obtained on a 1.54 mmol scale as a pale
yellow wax (217 mg, 43%); Rf 0.10 (1:3 ethyl acetate-heptanes); IR νmax/cm-1 3396, 2919, 2849, 2831,
1502, 1452; 1H-NMR δH (400 MHz, CDCl3) 7.93 (s, 1H), 7.85 (d, J = 3.0 Hz, 1H), 7.52 (d, J = 7.1 Hz,
2H), 7.38 (tt, J = 7.1, 1.7 Hz, 2H), 7.33 (tt, J = 7.2, 1.4 Hz, 1H), 6.92 (d, J = 8.9 Hz, 1H), 6.85 (dd,
13
J = 8.9, 3.0 Hz, 1H), 6.10 (s, 1H), 3.88 (s, 3H), 3.84 (s, 3H); C-NMR δC (100 MHz, CDCl3) 171.9,
153.8, 151.3, 150.2, 141.5, 128.8, 128.6, 126.8, 123.5, 118.4, 115.3, 114.5, 112.6, 73.9, 56.1, 56.0; m/z
LRMS (ES+) 328.33 (21%, [M+H]+), 311.30 (50), 310.33 (100, [M–OH]+).
[4-(2,4-Dimethoxyphenyl)thiazol-2-yl](phenyl)methanol (2d). Obtained on a 2.00 mmol scale as a
colourless solid (523 mg, 80%). An analytical sample was recrystallized from chloroform to give
colourless plates, m.p. 132.5-133.5 ºC (chloroform); Rf 0.19 (1:3 ethyl acetate-heptanes); IR νmax/cm-1
1
3149, 1612, 1582; H-NMR δH (400 MHz, CDCl3) 8.17 (d, J = 8.6 Hz, 1H), 7.74 (s, 1H), 7.52 (dd,
J = 8.3, 1.2 Hz, 2H), 7.41-7.31 (m, 3H), 6.59 (dd, J = 8.6, 2.4 Hz, 1H), 6.55 (d, J = 2.4 Hz, 1H), 6.08
(s, 1H), 3.91 (s, 3H), 3.85 (s, 3H); 13C-NMR δC (100 MHz, CDCl3) 171.5, 160.6, 158.0, 150.4, 141.6,
131.0, 128.8, 128.6, 126.9, 116.0, 104.9, 98.9, 74.0, 55.6 (2 signals); m/z LRMS (ES+) 328.31 (24%,
[M+H]+), 311.30 (48), 310.33 (100, [M–OH]+).
[4-(5-Bromo-2-methoxyphenyl)thiazol-2-yl](4-methylphenyl)methanol (2e). Obtained on a 1.00 mmol
scale as a pale yellow wax (273 mg, 67%); Rf 0.32 (1:3 ethyl acetate-heptanes); IR νmax/cm-1 3329,
2921, 2849, 1490, 1243, 1019; 1H-NMR δH (360 MHz, CDCl3) 8.37 (d, J = 2.6 Hz, 2H), 7.90 (s, 1H),
7.41 (d, J = 8.0 Hz, 2H), 7.39 (dd, J = 8.9, 2.6 Hz, 1H), 7.20 (d, J = 7.9 Hz, 1H), 6.85 (d, J = 8.9 Hz,
1H), 6.07 (s, 1H), 3.92 (s, 3H), 2.36 (s, 3H); 13C-NMR δC (90 MHz, CDCl3) 172.9, 156.3, 149.2,
138.84, 138.76, 133.0, 131.9, 129.9, 127.1, 124.9, 119.3, 113.8, 113.3, 74.0, 56.2, 21.7; m/z LRMS
(ES+) 374.28 (100%, [M(81Br)−OH]+), 372.27 (92, [M(79Br)−OH]+).

Molecules 2010, 15
6025
[4-(5-Bromo-2-methoxyphenyl)-thiazol-2-yl](4-trifluoromethylphenyl)methanol (2f). Obtained on a
1.00 mmol scale as a pale yellow oil (155 mg, 35%); Rf 0.31 (1:3 ethyl acetate-heptanes); IR νmax/cm-1
3146, 2937, 2840, 1492, 1322, 1247; 1H-NMR δH (360 MHz, CDCl3) 8.33 (d, J = 2.6 Hz, 1H), 7.91 (s,
1H), 7.67-7.61 (m, 4H), 7.38 (dd, J = 8.8, 2.6 Hz, 1H), 6.84 (d, J = 8.8 Hz, 1H), 6.16 (s, 1H), 3.90 (s,
3H); 13C-NMR δC (90 MHz, CDCl3) 171.3, 155.9, 149.3, 145.1, 132.6, 131.7, 130.7 (q,
2JCF = 32.5 Hz), 127.0, 125.8 (q, 3JCF = 3.4 Hz), 124.5, 124.1 (q, 1JCF = 272.4 Hz), 119.2, 113.4, 113.0,
73.2, 55.8; m/z LRMS (ES+) 428.19 (100%, [M(81Br)−OH]+), 426.24 (96, [M(79Br)−OH]+).
[4-(5-Bromo-2-methoxyphenyl)-thiazol-2-yl](4-chlorophenyl)methanol (2g). Obtained on a 1.00 mmol
scale as a colourless oil (365 mg, 89%); Rf 0.49 (1:3 ethyl acetate-heptanes); IR νmax/cm-1 3143, 2935,
2837, 1489, 1245; 1H-NMR δH (400 MHz, CDCl3) 8.34 (d, J = 2.6 Hz, 1H), 7.91 (s, 1H), 7.46-7.33 (m,
5H), 6.85 (d, J = 8.8 Hz, 1H), 6.07 (s, 1H), 3.91 (s, 3H); 13C-NMR δC (100 MHz, CDCl3) 171.5, 155.8,
149.1, 139.7, 134.4, 132.5, 131.5, 128.9, 128.1, 124.5, 119.0, 113.3, 112.9, 73.1, 55.8; m/z LRMS
(ES+) 396.26 (30%, [M(37Cl81Br)−OH]+), 394.25 (100, [M(35Cl81Br)−OH]+,[M(37Cl79Br)−OH]+),
392.30 (72, [M(35Cl79Br)−OH]+).
[4-(5-Bromo-2-methoxyphenyl)thiazol-2-yl](thiophen-2-yl)methanol (2h). Obtained on a 1.00 mmol
scale as a yellow wax (300 mg, 79%); Rf 0.36 (1:3 ethyl acetate-heptanes); IR νmax/cm-1 3232, 3157,
2834, 2360, 1498, 1473, 1458, 1436; 1H-NMR δH (400 MHz, CDCl3) 8.37 (d, J = 2.6 Hz, 1H), 7.94 (s,
1H), 7.37 (dd, J = 8.8, 2.6 Hz, 1H), 7.32 (dd, J = 5.1, 1.2 Hz, 1H), 7.15 (ddd, J = 3.5, 1.2, 0.8 Hz, 1H),
13
7.01 (dd, J = 5.1, 3.5 Hz, 1H), 6.85 (d, J = 8.8 Hz, 1H), 6.35 (d, J = 0.8 Hz, 1H), 3.92 (s, 3H); C-
NMR δC (100 MHz, CDCl3) 170.9, 155.9, 149.1, 144.8, 132.6, 131.5, 126.9, 126.3, 125.8, 124.6,
119.0, 113.4, 112.9, 70.0, 55.8; m/z LRMS (ES+) 366.28 (100%, [M(81Br)−OH]+), 364.27 (91,
[M(79Br)−OH]+).
[4-(5-Bromo-2-methoxyphenyl)thiazol-2-yl](4-methoxyphenyl)methanol (2i). Obtained on a 1.00 mmol
scale as a colourless oil (337 mg, 83%); Rf 0.21 (1:3 ethyl acetate-heptanes); IR νmax/cm-1 3371, 3143,
2933, 2836, 1610, 1589, 1509, 1242; 1H-NMR δH (400 MHz, CDCl3) 8.36 (d, J = 2.6 Hz, 1H), 7.89 (s,
1H), 7.41 (d, J = 8.6 Hz, 2H), 7.36 (dd, J = 8.8, 2.6 Hz, 1H), 6.90 (d, J = 8.6 Hz, 2H), 6.83 (d,
J = 8.8 Hz, 1H), 6.02 (s, 1H), 3.89 (s, 3H), 3.80 (s, 3H); 13C-NMR δC (100 MHz, CDCl3) 173.0, 160.1,
156.2, 149.4, 134.1, 132.9, 131.7, 128.5, 125.5, 119.3, 114.5, 113.7, 113.3, 73.9, 56.2, 55.7; m/z
LRMS (ES+) 390.29 (100%, [M(81Br)−OH]+), 388.29 (91, [M(79Br)−OH]+).
3.2.3. General procedure for oxidation of secondary alcohols with Dess-Martin periodinane
The relevant alcohol (0.550 mmol) was dissolved in dichloromethane (2.5 mL) and Dess-Martin
periodinane (15% solution in dichloromethane; 2.39 mL, 1.10 mmol) was added in one portion. The
resulting solution was stirred at r.t. for 6 h, followed by addition of 1 M aqueous NaOH (4 mL). After
stirring the resulting biphasic mixture for 5 min., diethyl ether was added (30 mL), the phases
separated and the aqueous layer extracted with diethyl ether (2 × 10 mL). The combined organic layers
were dried (Na2SO4) and concentrated, and the resulting crude residue filtered through a short plug of
silica gel (eluting with 1:19 ethyl acetate-heptanes) to give the ketones 3a-i.

Molecules 2010, 15
6026
[4-(5-Bromo-2-methoxyphenyl)thiazol-2-yl](phenyl)methanone (3a). Obtained on a 0.550 mmol scale
as a pale yellow solid (202 mg, 86%). An analytical sample was recrystallized from chloroform to give
yellow needles, m.p. 131.0-133.0 ºC (chloroform); Rf 0.34 (1:3 ethyl acetate-heptanes); IR νmax/cm-1
1
3144, 3062, 3001, 2839, 1630, 1592, 1574; H-NMR δH (360 MHz, CDCl3) 8.57 (dtd, J = 7.6, 1.4,
0.6 Hz, 2H), 8.37 (d, J = 2.6 Hz, 1H), 8.32 (s, 1H), 7.67 (tt, J = 7.4, 1.4 Hz, 1H), 7.57 (t, J = 7.6 Hz,
13
2H), 7.43 (dd, J = 8.8, 2.6 Hz, 1H), 6.89 (d, J = 8.8 Hz, 1H), 3.96 (s, 3H); C-NMR δC (90 MHz,
CDCl3) 183.9, 165.7, 156.1, 152.0, 135.2, 133.7, 132.6, 132.0, 131.3, 128.5, 125.4, 124.4, 113.5,
113.1, 55.9; m/z LRMS (ES+) 376.29 (100%, [M81Br+H]+), 374.28 (94, [M79Br+H]+).
[4-(5-Chloro-2-methoxyphenyl)thiazol-2-yl](phenyl)methanone (3b). Obtained on a 1.36 mmol scale
as a pale yellow solid (405 mg, 90%). An analytical sample was recrystallized from dichloromethane
to give yellow needles, m.p. 132.0-133.0 ºC (dichloromethane); Rf 0.30 (1:3 ethyl acetate-heptanes);
1
IR νmax/cm-1 3144, 3067, 3006, 2838, 1630, 1593, 1574; H-NMR δH (360 MHz, CDCl3) 8.57 (dd,
J = 7.2, 1.3 Hz, 2H), 8.32 (s, 1H), 8.23 (d, J = 2.7 Hz, 1H), 7.67 (tt, J = 7.4, 1.3 Hz, 1H), 7.57 (tt,
J = 7.3, 1.3 Hz, 2H), 7.28 (dd, J = 8.8, 2.7 Hz, 1H), 6.92 (d, J = 8.8 Hz, 1H), 3.95 (s, 3H); 13C-NMR δC
(90 MHz, CDCl3) 184.0, 165.7, 155.7, 152.1, 135.2, 133.7, 131.3, 129.8, 129.1, 128.5, 126.1, 125.4,
124.0, 112.6, 55.9; m/z LRMS (ES+) 332.26 (38%, [M37Cl+H]+), 330.26 (100, [M35Cl+H]+).
[4-(2,5-Dimethoxyphenyl)thiazol-2-yl](phenyl)methanone (3c). Obtained on a 0.580 mmol scale as a
pale yellow solid (101 mg, 53%). An analytical sample was recrystallized from chloroform to give
yellow needles, m.p. 107.5-109.5 ºC (chloroform); Rf 0.30 (1:3 ethyl acetate-heptanes); IR νmax/cm-1
1
3122, 2995, 2827, 1638; H-NMR δH (360 MHz, CDCl3) 8.61 (dd, J = 7.3, 1.2 Hz, 2H), 8.34 (s, 1H),
7.88 (d, J = 3.0 Hz, 1H), 7.64 (t, J = 7.4 Hz, 1H), 7.54 (t, J = 7.6 Hz, 2H), 6.94 (d, J = 9.0 Hz, 1H),
6.88 (dd, J = 9.0, 3.0 Hz, 1H), 3.91 (s, 3H), 3.84 (s, 3H); 13C-NMR δC (90 MHz, CDCl3) 171.9, 153.8,
151.3, 150.2, 141.5, 128.8, 128.6, 126.8, 123.5, 118.4, 115.3, 114.5, 112.6, 73.9, 56.1, 56.0; m/z
LRMS (ES+) 326.32 (100%, [M+H]+).
[4-(2,4-Dimethoxyphenyl)thiazol-2-yl](phenyl)methanone (3d). Obtained on a 1.12 mmol scale as a
pale yellow solid (363 mg, 100%). An analytical sample was recrystallized from chloroform to give
yellow needles, m.p. 106.0-107.5 ºC (chloroform); Rf 0.30 (1:3 ethyl acetate-heptanes); IR νmax/cm-1
1
3141, 3071, 1643, 1611, 1597, 1578; H-NMR δH (360 MHz, CDCl3) 8.61 (dd, J = 8.3, 1.3 Hz, 2H),
8.22 (d, J = 8.6 Hz, 1H), 8.17 (s, 1H), 7.63 (tt, J = 7.4, 1.3 Hz, 1H), 7.54 (t, J = 7.6 Hz, 2H), 6.63 (dd,
J = 8.6, 2.4 Hz, 1H), 6.56 (d, J = 2.4 Hz, 1H), 3.93 (s, 3H), 3.85 (s, 3H); 13C-NMR δC (90 MHz,
CDCl3) 184.4, 165.6, 161.4, 158.6, 154.1, 135.9, 133.9, 131.8, 131.4, 128.8, 123.0, 116.4, 105.5, 99.1,
55.9 (2 signals); m/z LRMS (ES+) 326.29 (100%, [M+H]+).
[4-(5-Bromo-2-methoxyphenyl)-thiazol-2-yl](4-methylphenyl)methanone (3e). Obtained on
a
0.64 mmol scale as a yellow solid (130 mg, 52%). An analytical sample was recrystallized from
chloroform to give yellow needles, m.p. 136.0-138.0 ºC (chloroform); Rf 0.42 (1:3 ethyl acetate-
1
heptanes); IR νmax/cm-1 3145, 2838, 1626, 1603, 1567; H-NMR δH (400 MHz, CDCl3) 8.50 (d,
J = 8.2 Hz, 2H), 8.38 (d, J = 2.3 Hz, 1H), 8.30 (s, 1H), 7.43 (dd, J = 8.8, 2.3 Hz, 1H), 7.37 (d,
J = 8.2 Hz, 2H), 6.89 (d, J = 8.8 Hz, 1H), 3.96 (s, 3H), 2.48 (s, 3H); 13C-NMR δC (100 MHz, CDCl3)

Molecules 2010, 15
6027
183.6, 166.1, 156.2, 151.9, 144.8, 132.70, 132.66, 132.0, 131.5, 129.3, 125.2, 124.6, 113.5, 113.1,
55.9, 22.0; m/z LRMS (ES+) 390.28 (100%, [M(81Br)+H]+), 388.27 (92, [M(79Br)+H]+).
[4-(5-Bromo-2-methoxyphenyl)thiazol-2-yl](4-trifluoromethylphenyl)methanone (3f). Obtained on a
0.64 mmol scale as a yellow solid (240 mg, 84%). An analytical sample was recrystallized from
chloroform to give yellow needles, m.p. 144.5-145.5 ºC (chloroform); Rf 0.39 (1:3 ethyl acetate-
1
heptanes); IR νmax/cm-1 3138, 3089, 3016, 2946, 2842, 1645; H-NMR δH (360 MHz, CDCl3) 8.66 (d,
J = 8.1 Hz, 2H), 8.36 (s, 1H), 8.31 (d, J = 2.6 Hz, 1H), 7.83 (d, J = 8.1 Hz, 2H), 7.45 (dd, J = 8.8,
2.6 Hz, 1H), 6.90 (d, J = 8.8 Hz, 1H), 3.97 (s, 3H); 13C-NMR δC (90 MHz, CDCl3) 183.3, 165.3, 156.5,
2
3
152.7, 138.4, 135.1 (q, JCF = 32.5 Hz), 132.9, 132.7, 131.9, 126.3, 125.8 (q, JCF = 4.1 Hz), 124.5,
124.1 (q, 1JCF = 273.4 Hz), 113.9, 113.5, 56.3; m/z LRMS (ES+) 444.19 (100%, [M(81Br)+H]+), 442.18
(92, [M(79Br)+H]+).
[4-(5-Bromo-2-methoxyphenyl)thiazol-2-yl](4-chlorophenyl)methanone (3g). Obtained on
a
0.75 mmol scale as a yellow solid (300 mg, 97%). An analytical sample was recrystallized from
chloroform to give yellow needles, m.p. 150.5-153.0 ºC (chloroform); Rf 0.46 (1:3 ethyl acetate-
1
heptanes); IR νmax/cm-1 3147, 3081, 2836, 1635, 1584; H-NMR δH (360 MHz, CDCl3) 8.54 (d,
J = 8.7 Hz, 2H), 8.32 (s, 1H), 8.32 (d, J = 2.6 Hz, 1H), 7.54 (d, J = 8.7 Hz, 2H), 7.43 (dd, J = 8.8,
13
2.6 Hz, 1H), 6.89 (d, J = 8.8 Hz, 1H), 3.96 (s, 3H); C-NMR δC (100 MHz, CDCl3) 183.0, 165.7,
156.5, 152.5, 140.8, 133.8, 133.0, 132.9, 132.5, 129.2, 126.1, 124.6, 113.8, 113.4, 56.3; m/z LRMS
(ES+) 412.13 (30%, [M(37Cl81Br)+H]+), 410.18 (100, [M(35Cl81Br)+H]+, [M(37Cl79Br)+H]+), 408.17
(75, [M(35Cl79Br)+H]+).
[4-(5-Bromo-2-methoxyphenyl)thiazol-2-yl](thiophen-2-yl)methanone (3h). Obtained on a 0.72 mmol
scale as a yellow solid (75 mg, 27%). An analytical sample was recrystallized from chloroform to give
yellowish brown needles, m.p. 146.5-147.5 ºC (chloroform); Rf 0.46 (1:3 ethyl acetate-heptanes);
IR νmax/cm-1 3143, 2844, 1617; 1H-NMR δH (400 MHz, CDCl3) 8.62 (dd, J = 3.9, 1.2 Hz, 1H), 8.47 (d,
J = 2.6 Hz, 1H), 8.33 (s, 1H), 7.85 (dd, J = 4.9, 1.2 Hz, 1H), 7.45 (dd, J = 8.8, 2.6 Hz, 1H), 7.27 (dd,
13
J = 4.9, 3.9 Hz, 1H), 6.91 (d, J = 8.8 Hz, 1H), 3.97 (s, 3H); C-NMR δC (100 MHz, CDCl3) 175.7,
164.9, 156.1, 151.9, 139.3 (2 signals), 136.8, 132.7, 132.1, 128.2, 125.2, 124.3, 113.5, 113.0, 55.9; m/z
LRMS (ES+) 382.28 (100%, [M(81Br)+H]+), 380.25 (94, [M(79Br)+H]+), 316.28 (48), 314.27 (45),
298.26 (52), 296.25 (49).
[4-(5-Bromo-2-methoxyphenyl)thiazol-2-yl](4-methoxyphenyl)methanone (3i). Obtained on
a
0.45 mmol scale as a yellow solid (134 mg, 74%). An analytical sample was recrystallized from
chloroform to give pale yellow needles, m.p. 171.0-171.5 ºC (chloroform); Rf 0.39 (1:3 ethyl acetate-
1
heptanes); IR νmax/cm-1 3147, 2838, 1627, 1588; H-NMR δH (400 MHz, CDCl3) 8.65 (d, J = 9.1 Hz,
2H), 8.39 (d, J = 2.6 Hz, 1H), 8.30 (s, 1H), 7.45 (dd, J = 8.8, 2.6 Hz, 1H), 7.06 (d, J = 9.1 Hz, 2H),
13
6.92 (d, J = 8.8 Hz, 1H), 3.98 (s, 3H), 3.94 (s, 3H); C-NMR δC (100 MHz, CDCl3) 182.3, 166.6,
164.4, 156.2, 151.8, 133.9, 132.7, 132.0, 128.0, 125.0, 124.7, 114.0, 113.6, 113.2, 56.0, 55.7; m/z
LRMS (ES+) 406.28 (100%, [M(81Br)+H]+), 404.26 (92, [M(79Br)+H]+).

Molecules 2010, 15
6028
3.2.4. General procedure for demethylation with BBr3
The appropriate ketone (0.086 mmol) was suspended in dichloromethane (2 mL) and cooled to
-78 ºC. Neat BBr3 (41 μL, 0.44 mmol) was added dropwise via microsyringe, whereupon the mixture
turned black. The mixture was stirred at this temperature for 2 h and then allowed to gradually warm to
r.t. over the course of 22 h. After cooling to -78 ºC, the reaction was quenched by careful addition of
methanol (1 mL), saturated aqueous NaHCO3 (1 mL) and water (5 mL), followed by warming to
ambient temperature. The mixture was extracted with ethyl acetate (3 × 10 mL), the combined organic
layers dried (Na2SO4) and concentrated, and the resulting residue filtered through a short plug of silica
gel (eluting with 1:3 ethyl acetate-heptanes) to give a crude product which was typically further
purified by preparative HPLC and recrystallization from ethanol to yield the phenols 4a, 4b and 4d-i.
[4-(5-Bromo-2-hydroxyphenyl)thiazol-2-yl](phenyl)methanone (4a). Obtained on a 0.086 mmol scale
as pale yellow platelets (2.6 mg, 8%), m.p. 154.0-155.0 ºC (ethanol); Rf 0.23 (1:3 ethyl acetate-
1
heptanes); IR νmax/cm-1 3082, 1643, 1597, 1574; H-NMR δH (500 MHz, CDCl3) 10.93 (s, 1H), 8.22
(dd, J = 7.8, 1.3 Hz, 2H), 7.99 (s, 1H), 7.79 (d, J = 2.4 Hz, 1H), 7.69 (tt, J = 7.4, 1.3 Hz, 1H), 7.59
13
(ddt, J = 7.8, 7.4, 1.6 Hz, 2H), 7.38 (dd, J = 8.8, 2.4 Hz, 1H), 6.93 (d, J = 8.8 Hz, 1H); C-NMR δC
(125 MHz, CDCl3) 184.1, 166.7, 155.1, 154.6, 135.1, 134.2, 133.7, 130.4, 129.0, 128.9, 120.2, 120.1,
118.6, 111.8; m/z LRMS (ES–) 360.25 (100%, [M(81Br)–H]–), 358.24 (88, [M(79Br)–H]–); HRMS
(ES+) found 359.9693, C16H1179BrNO2S+ requires 359.9688.
[4-(5-Chloro-2-hydroxyphenyl)thiazol-2-yl](phenyl)methanone (4b). Obtained on a 0.58 mmol scale,
from preparative HPLC of a 40 mg aliquat of a total of 123 mg crude product followed by
recrystallization from ethanol, as pale yellow platelets (13 mg, 22% from aliquat), m.p. 139.0-143.5 ºC
1
(ethanol); Rf 0.28 (1:3 ethyl acetate-heptanes); IR νmax/cm-1 3082, 2925, 1728, 1640, 1596, 1576; H-
NMR δH (400 MHz, CDCl3) 10.90 (s, 1H), 8.23 (dd, J = 7.7, 1.4 Hz, 2H), 7.99 (s, 1H), 7.71-7.56 (m,
4H), 7.25 (dd, J = 8.8, 2.6 Hz, 1H), 6.98 (d, J = 8.8 Hz, 1H); δC (100 MHz, CDCl3) 184.1, 166.7,
154.7, 154.6, 135.1, 134.2, 130.8, 130.4, 128.9, 126.1, 124.8, 120.2, 119.7, 117.9; m/z LRMS (ES–)
316.35 (38%, [M(37Cl)–H]–), 314.35 (100, [M(35C)l–H]–), 183.20 (40); HRMS (ES+) found 316.0189,
C16H1135ClNO2S+ requires 316.0194.
[4-(2,4-Dihydroxyphenyl)thiazol-2-yl](phenyl)methanone (4d). Obtained on a 0.81 mmol scale (but the
amount BBr3 used was 8 equivalents), from preparative HPLC of a 36 mg aliquat of a total of 150 mg
crude product, as an orange, amorphous solid (29 mg, 50% from aliquat), m.p. 168.0 ºC
(decomposition); Rf 0.11 (1:3 ethyl acetate-heptanes); IR νmax/cm-1 3415, 3123, 2535, 2231, 1625,
1
1597; H-NMR δH (400 MHz, CD3OD) 8.33 (dd, J = 7.9, 1.3 Hz, 2H), 8.25 (s, 1H), 7.79 (d,
J = 8.5 Hz, 1H), 7.70 (tt, J = 7.4, 1.3 Hz, 1H), 7.58 (tt, J = 7.7, 1.6 Hz, 2H), 6.41 (dd, J = 8.5, 2.3 Hz,
13
1H), 6.39 (d, J = 2.3 Hz, 1H); C-NMR δC (100 MHz, CD3OD) 185.5, 166.4, 160.6, 158.2, 157.0,
136.8, 134.7, 131.6, 130.2, 129.6, 120.9, 112.1, 108.8, 104.1; m/z LRMS (ES–) 296.38 (100%, [M–H]–),
165.20 (31); HRMS (ES+) found 298.0526, C16H12NO3S+ requires 298.0532.

Molecules 2010, 15
6029
[4-(5-Bromo-2-hydroxyphenyl)thiazol-2-yl](4-methylphenyl)methanone (4e). Obtained on a 0.31 mmol
scale, after chromatography on silica gel (1:9 ethyl acetate-heptanes) followed by recrystallization
from ethanol, as yellow needles (10 mg, 9%), m.p. 165.0-168.5 ºC (ethanol); Rf 0.46 (1:3 ethyl acetate-
1
heptanes); IR νmax/cm-1 3080, 1639, 1604; H-NMR δH (400 MHz, CDCl3) 11.0 (br s, 1H), 8.13 (d,
J = 8.3 Hz, 2H), 7.96 (s, 1H), 7.78 (d, J = 2.4 Hz, 1H), 7.39-7.35 (m, 3H), 6.93 (d, J = 8.8 Hz, 1H),
13
2.47 (s, 3H); C-NMR δC (100 MHz, CDCl3) 183.5, 166.8, 154.9, 154.2, 145.3, 133.5, 132.3, 130.5,
129.6, 128.8, 120.0, 119.9, 118.5, 111.6, 21.9; m/z LRMS (ES–) 374.41 (83%, [M(81Br)–H]–), 372.39
(100, [M(79Br)–H]–); HRMS (ES+) found 373.9841, C17H1279BrNO2S+ requires 373.9845.
[4-(5-Bromo-2-hydroxyphenyl)thiazol-2-yl](4-trifluoromethylphenyl)methanone (4f). Obtained on a
0.23 mmol scale, after preparative HPLC followed by recrystallization from ethanol, as pale yellow
platelets (15 mg, 15%), m.p. 138.0-138.5 ºC (ethanol); Rf 0.38 (1:3 ethyl acetate-heptanes);
1
IR νmax/cm-1 3099, 2359, 1658, 1576; H-NMR δH (400 MHz, CDCl3) 10.7 (br s, 1H), 8.32 (d,
J = 8.7 Hz, 2H), 8.05 (s, 1H), 7.85 (d, J = 8.7 Hz, 2H), 7.79 (d, J = 2.4 Hz, 1H), 7.39 (dd, J = 8.8,
13
2.4 Hz, 1H), 6.93 (d, J = 8.8 Hz, 1H); C-NMR δC (100 MHz, CDCl3) 183.1, 165.6, 154.80, 154.77,
2
3
137.8, 135.2 (q, JCF = 35.8 Hz), 133.8, 130.6, 128.9, 125.8 (q, JCF = 3.7 Hz), 123.5 (q,
1JCF = 272.9 Hz), 120.9, 120.0, 118.2; m/z LRMS (ES–) 428.26 (100%, [M(81Br)–H]–), 426.29 (95,
[M(79Br)–H]–); HRMS (ES+) found 427.9571, C17H1079BrF3NO2S+ requires 427.9562.
[4-(5-Bromo-2-hydroxyphenyl)thiazol-2-yl](4-chlorophenyl)methanone (4g). Obtained on a 0.27 mmol
scale, after preparative HPLC followed by recrystallization from ethanol, as orange platelets (15 mg,
14%), m.p. 162.0-163.5 ºC (ethanol); Rf 0.46 (1:3 ethyl acetate-heptanes); IR νmax/cm-1 3104, 1634,
1584; 1H-NMR δH (400 MHz, CDCl3) 8.18 (d, J = 8.8 Hz, 2H), 8.00 (1s, 1H), 7.77 (d, J = 2.4 Hz, 1H),
13
7.56 (d, J = 8.8 Hz, 2H), 7.38 (dd, J = 8.8, 2.4 Hz, 1H), 6.92 (d, J = 8.8 Hz, 1H); C-NMR δC (100
MHz, CDCl3) 182.7, 166.1, 154.8, 154.5, 140.8, 133.7, 133.2, 131.7, 129.2, 128.9, 120.5, 120.0, 118.3,
111.8; m/z LRMS (ES–) 396.26 (29%, [M(37Cl81Br)–H]–), 394.31 (100, [M(37Cl79Br)–H]–,
[M(35Cl81Br)–H]–), 392.36 (84, [M(35Cl79Br)–H]–); HRMS (ES+) found 393.9285,
C16H1035Cl79BrNO2S+ requires 393.9299.
[4-(5-Bromo-2-hydroxyphenyl)thiazol-2-yl](thiophen-2-yl)methanone (4h). Obtained on a 0.14 mmol
scale, after chromatography on silica gel (1:9 ethyl acetate-heptanes) followed by recrystallization
from ethanol, as yellow platelets (52 mg, 89%), m.p. 165.0-166.0 ºC (ethanol); Rf 0.44 (1:3 ethyl
1
acetate-heptanes); IR νmax/cm-1 3085, 1616, 1510, 1409; H-NMR δH (400 MHz, CDCl3) 10.8 (s, 1H),
8.34 (dd, J = 3.9, 1.2 Hz, 1H), 7.98 (1s, 1H), 7.86 (dd, J = 4.9, 1.2 Hz, 1H), 7.77 (d, J = 2.4 Hz, 1H),
13
7.40 (dd, J = 8.8, 2.4 Hz, 1H), 7.28 (dd, J = 4.9, 3.9 Hz, 1H), 6.97 (d, J = 8.8 Hz, 1H); C-NMR δC
(100 MHz, CDCl3) 174.7, 166.6, 154.6, 154.3, 138.2, 136.7, 136.3, 133.6, 129.0, 128.6, 120.5, 119.9,
118.5, 111.8; m/z LRMS (ES–) 366.35 (100%, [M(81Br)–H]–), 364.27 (64, [M(79Br)–H]–); HRMS
79
+
(ES+) found 365.9248, C14H9 BrNO2S2 requires 365.9253.
[4-(5-Bromo-2-hydroxyphenyl)thiazol-2-yl](4-methoxyphenyl)methanone (4i). Obtained on
a
0.12 mmol scale, after preparative HPLC followed by recrystallization from ethanol, as yellow-orange
platelets (3 mg, 6%), m.p. 146.0-147.0 ºC (ethanol); Rf 0.33 (1:3 ethyl acetate-heptanes); IR νmax/cm-1

Molecules 2010, 15
6030
3097, 2916, 1633, 1596, 1568; 1H-NMR δH (400 MHz, CDCl3) 8.29 (d, J = 9.0 Hz, 2H), 7.95 (s, 1H),
7.78 (d, J = 2.4 Hz, 1H), 7.38 (dd, J = 8.8, 2.4 Hz, 1H), 7.06 (d, J = 9.0 Hz, 2H), 6.94 (d, J = 4.0 Hz,
13
1H), 3.92 (s, 3H); C-NMR δC (100 MHz, CDCl3) 182.2, 167.5, 164.7, 155.0, 154.2, 133.6, 133.1,
129.0, 127.7, 120.0, 119.8, 118.7, 114.4, 111.8, 55.8; m/z LRMS (ES–) 390.34 (100%, [M(81Br)–H]–),
388.39 (64, [M(79Br)–H]–); HRMS (ES+) found 389.9805, C17H1379BrNO3S+ requires 389.9794.
3.2.5. Demethylation with cerium(III) ammonium nitrate
[4-(2,4-Dihydroxyphenyl)thiazol-2-yl](phenyl)methanone (4c). Ketone 3c (27 mg, 0.083 mmol) was
suspended in a mixture of acetonitrile (2 mL) and water (1 mL). Cerium(III) ammonium nitrate
(110 mg, 0.20 mmol) was added in one portion and the resulting mixture stirred at r.t. for 1 h, at which
point LC/MS analysis showed complete consumption of starting material. The mixture was diluted
with water (5 mL) and extracted with diethyl ether (3 × 20 mL), the combined organic layers washed
with brine (5 mL), dried (Na2SO4) and concentrated. The residue was dissolved in a solution of
Na2S2O3 (450 mg, 2.8 mmol) in a mixture of water (3 mL) and dioxane (3 mL) and the resulting
solution stirred at r.t. for 16 h. The mixture was diluted with water (5 mL), extracted with ethyl acetate
(3 × 10 mL), the combined organic layers dried (Na2SO4) and concentrated, and the resulting residue
purified by chromatography on silica gel (eluting with 1:3 ethyl acetate-heptanes) and recrystallization
from acetone-heptane to give the hydroquinone 4c as pale yellow platelets (10 mg, 41%), m.p.
191.0-192.0 ºC (acetone-heptane); Rf 0.06 (1:3 ethyl acetate-heptanes); IR νmax/cm-1 3415, 3130, 2923,
1
1734, 1636, 1595, 1575; H-NMR δH (400 MHz, acetone-d6) 9.66 (s, 1H), 8.56 (s, 1H), 8.22 (dd,
J = 7.7, 1.3 Hz, 2H), 7.95 (s, 1H), 7.76 (tt, J = 7.4, 1.3 Hz, 1H), 7.65 (t, J = 7.7 Hz, 2H), 7.52 (d,
13
J = 2.8 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 6.80 (dd, J = 8.7, 2.8 Hz, 1H); C-NMR δC (100 MHz,
acetone-d6) 184.7, 166.6, 155.9, 151.3, 149.7, 136.4, 134.5, 131.4, 129.5, 123.3, 119.4, 118.7, 118.5,
114.5; m/z LRMS (ES–) 296.34 (100%, [M–H]–), 165.18(35); HRMS (ES+) found 298.0532,
C16H12NO3S+ requires 298.0532.
3.2.6. Demethylation with dodecanethiolate
[4-(5-Bromo-2-hydroxyphenyl)thiazol-2-yl](4-hydroxyphenyl)methanone (4j). Ketone 3i (40 mg,
0.10 mmol) and NaOH (24 mg, 0.60 mmol) were weighed into a 2 mL Emrys microwave vial. The vial
was capped and flushed with nitrogen, followed by the addition of N-methylpyrrolidone (1 mL) and
dodecanethiol (72 μL, 0.30 mmol) via syringe. The reaction mixture was subjected to microwave
irradiation at a fixed temperature of 130 ºC (variable power) for 15 min. After cooling to ambient
temperature, the reaction mixture was acidified with 1M HCl (until pH ≈ 1) and extracted with ethyl
acetate (3 × 5 mL). The combined organic layers were washed with brine (5 mL), dried (Na2SO4) and
concentrated under reduced pressure. The crude residue was purified by chromatography on silica gel
(gradient 1:9 to 1:3 ethyl acetate-heptanes) and preparative HPLC to yield the phenol 4j as a pale
yellow, amorphous solid (17 mg, 45%), mp 195.0-198.5 ºC; Rf 0.16 (1:3 ethyl acetate-heptanes);
IR νmax/cm-1 3370, 3093, 1706, 1628, 1591, 1441; 1H-NMR δH (400 MHz, acetone-d6) 10.64 (br s, 1H),
8.67 (s, 1H), 8.38 (d, J = 8.9 Hz, 2H), 8.20 (d, J = 2.5 Hz, 1H), 7.40 (dd, J = 8.7, 2.5 Hz, 1H), 7.07 (d,
13
J = 8.9 Hz, 2H), 7.00 (d, J = 8.7 Hz, 1H); C-NMR δC (100 MHz, acetone-d6) 182.5, 167.9, 163.9,
155.6, 153.7, 134.2, 133.4, 131.2, 127.7, 123.7, 121.5, 120.0, 116.4, 112.1; m/z LRMS (ES–) 376.30

Molecules 2010, 15
6031
+
(100%, [M(81Br)–H]–), 374.35 (78, [M(79Br)–H]–); HRMS (EI+) found 374.9560, C16H1079BrNO3
requires 374.9565.
4. Conclusions
In conclusion, we have synthesized a focused library of ten [4-(2-hydroxyphenyl)thiazol-2-
yl]methanones according to a four-step procedure starting from 4-bromothiazol-2-ylcarboxaldehyde.
The Suzuki coupling, addition of aryl Grignards, and the oxidation generally proceeded in modest to
excellent yields. The final demethylation proved to be sluggish, but still produced enough material for
characterization and biological evaluation. The target compounds were isolated in 2.2-24.4% total
yields. None of the compounds were active as putative T3S inhibitors in whole-cell bacterial assays.
The target protein has not been determined for the salicylidene acylhydrazides and all assays are
therefore cell-based. This means that [4-(2-hydroxyphenyl)thiazol-2-yl]methanones that actually
interact with the same target as the salicylidene acylhydrazides still do not turn up as an active due to
other factors such as lack of permeability or rapid metabolism. In addition it cannot be excluded that
the salicylidene acylhydrazides target more than one protein critical for T3S function and optimization
of binding to more than one target by replacement of the central scaffold is likely to be challenging.
Even if binding to one target is maintained or even improved, binding to other targets might be lost
with lack of activity as overall result. Another explanation is that the thiazole scaffold does not
properly mimic biophysical properties and the bioactive conformation of the salicylidene
acylhydrazides. The compounds in the focused library are all novel and little information is published
on related structures. A SciFinder search on the general functionalized thiazole structure shown in
Figure 1d (performed 02-07-2010) resulted in ten substances in a total of three patents and one
publication [20-23]. In addition, replacement of the salicylidene acylhydrazide scaffold with a mimic is
of importance since the compound class has delivered biologically active molecules in a number of
human and microbial systems as exemplified by several recent publications [24-35].
Acknowledgements
We thank the Swedish Research Council and the Carl Trygger Foundation for financial support.
References and Notes
1. Hueck, C.J. Type III protein secretion systems in bacterial pathogens of animals and plants.
Microbiol. Mol. Biol. Rev. 1998, 62, 379-433.
2. Rasko, D.A.; Sperandio, V. Anti-virulence strategies to combat bacteria-mediated disease. Nat.
Rev. Drug Discov. 2010, 9, 117-128.
3. Baron, C. Antivirulence drugs to target bacterial secretion systems. Curr. Opin. Microbiol. 2010,
13, 100-105.
4. Keyser, P.; Elofsson, M.; Rosell, S.; Wolf-Watz, H. Virulence blockers as alternatives to
antibiotics: type III secretion inhibitors against Gram-negative bacteria. J. Int. Med. 2008, 264,
17-29.

Molecules 2010, 15
6032
5. Nordfelth, R.; Kauppi, A.M.; Norberg, H.A.; Wolf-Watz, H.; Elofsson, M. Small-molecule
inhibitors specifically targeting type III secretion. Infect. Immun. 2005, 73, 3104-3114.
6. Muschiol, S.; Bailey, L.; Gylfe, A.; Sundin, C.; Hultenby, K.; Bergstrom, S.; Elofsson, M.; Wolf-
Watz, H.; Normark, S.; Henriques-Normark, B. A small-molecule inhibitor of type III secretion
inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc. Nat. Acad. Sci.
USA 2006, 103, 14566-14571.
7. Wolf, K.; Betts, H.J.; Chellas-Gery, B.; Hower, S.; Linton, C.N.; Fields, K.A. Treatment of
Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system
disrupts progression of the chlamydial developmental cycle. Mol. Microbiol. 2006, 61,
1543-1555.
8. Bailey, L.; Gylfe, A.; Sundin, C.; Muschiol, S.; Elofsson, M.; Nordstrom, P.; Henriques-Normark,
B.; Lugert, R.; Waldenstrom, A.; Wolf-Watz, H., et al., Small molecule inhibitors of type III
secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett. 2007, 581,
587-595.
9. Slepenkin, A.; Enquist, P.A.; Hagglund, U.; de la Maza, L.M.; Elofsson, M.; Peterson, E.M.
Reversal of the antichlaraydial activity of putative type III secretion inhibitors by iron. Infect.
Immun. 2007, 75, 3478-3489.
10. Negrea, A.; Bjur, E.; Ygberg, S.E.; Elofsson, M.; Wolf-Watz, H.; Rhen, M. Salicylidene
acylhydrazides that affect type III protein secretion in Salmonella enterica serovar Typhimurium.
Antimicrob. Agents Chemother. 2007, 51, 2867-2876.
11. Hudson, D.L.; Layton, A.N.; Field, T.R.; Bowen, A.J.; Wolf-Watz, H.; Elofsson, M.; Stevens,
M.P.; Galyov, E.E. Inhibition of type III secretion in Salmonella enterica serovar typhimurium by
small-molecule inhibitors. Antimicrob. Agents Chemother. 2007, 51, 2631-2635.
12. Veenendaal, A.K.J.; Sundin, C.; Blocker, A.J. Small-molecule type III secretion system inhibitors
block assembly of the shigella type III secreton. J. Bacteriol. 2009, 191, 563-570.
13. Tree, J.J.; Wang, D.; McInally, C.; Mahajan, A.; Layton, A.; Houghton, I.; Elofsson, M.; Stevens,
M.P.; Gally, D.L.; Roe, A.J. Characterization of the effects of salicylidene acylhydrazide
compounds on type III secretion in Escherichia coli O157:H7. Infect. Immun. 2009, 77,
4209-4220.
14. Chu, H.; Slepenkin, A.; Elofsson, M.; Keyser, P.; de la Maza, L.; Peterson, E.M. Candidate
vaginal microbicides with activity against Chlamydia trachomatis and Neisseria gonorrhoeae. Int.
J. Antimicrob. Agents 2010, 36, 145-150.
15. Dahlgren, M.K.; Zetterström, C.E.; Gylfe, A.; Linusson, A.; Elofsson, M. Statistical molecular
design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of
type III secretion in the Gram-negative bacterium Yersinia. Bioorg. Med. Chem. 2010, 18,
2686-2703.
16. Dahlgren, M.K.; Öberg, C.T.; Wallin, E.A.; Jansson, P.G.; Elofsson, M. Synthesis of 2-(2-
Aminopyrimidine)-2,2-difluoroethanols as Potential Bioisosters of Salicylidene Acylhydrazides.
Molecules 2010, 15, 4423-4438.
17. Sandy, M.; Butler, A. Microbial Iron Acquisition: Marine and Terrestrial Siderophores. Chem.
Rev. 2009, 109, 4580-4595.

Molecules 2010, 15
6033
18. Chae, J. Practical demethylation of aryl methyl ethers using an odorless thiol reagent. Arch.
Pharm. Res. 2008, 31, 305-309.
19. Kauppi, A.M.; Nordfelth, R.; Uvell, H.; Wolf-Watz, H.; Elofsson, M. Targeting bacterial
virulence: Inhibitors of type III secretion in Yersinia. Chem. Biol. 2003, 10, 241-249.
20. Doyle, K.J. Compounds, compositions and methods comprising thiazole derivatives. WO Patent
131952, 29 October 2009.
21. Doyle, K.J.; Jones, G.P.; Russell, M.G.N.; Bruckner, S.; Macritchie, J.A.; Peach, J.
Heteroaromatic derivatives as CFTR inhibitors and their pharmaceutical compositions,
preparation and use in the treatment of diarrhea and polycystic kidney disease. US Patent
0144,733, 10 June 2010.
22. Doyle, K.J.; Jones, G.P.; Russell, M.G.N.; Bruckner, S.; Macritchie, J.A.; Peach, J.
Heteroaromatic compounds as CFTR inhibitors, compositions, their preparation and use in the
treatment of diarrhea and polycystic kidney disease. WO Patent 033626, 25 March 2010.
23. Voegtli, W.; Sorkin, E.; Erlenmeyer, H. The properties of some 4-(o-hydroxyphenyl)thiazoles.
Helv. Chim. Acta 1950, 33, 1297-1303.
24. Manvar, A.; Malde, A.; Verma, J.; Virsodia, V.; Mishra, A.; Upadhyay, K.; Acharya, H.
Coutinho, E. and Shah, A., Synthesis, anti-tubercular activity and 3D-QSAR study of coumarin-4-
acetic acid benzylidene hydrazides. Eur. J. Med. Chem. 2008, 43, 2395-2403.
25. Yang, H.Y.; Shen, Y.; Chen, J.H.; Jiang, Q.F.; Leng, Y.; Shen, J.H. Structure-based virtual
screening for identification of novel 11 beta-HSD1 inhibitors. Eur. J. Med. Chem. 2009, 44,
1167-1171.
26. Liu, W.Y.; Li, H.Y.; Zhao, B.X.; Shin, D.S.; Lian, S.; Miao, J.Y. Synthesis of novel ribavirin
hydrazone derivatives and anti-proliferative activity against A549 lung cancer cells. Carbohydr.
Res. 2009, 344, 1270-1275.
27. Vicini, P.; Incerti, M.; La Colla, P.; Loddo, R. Anti-HIV evaluation of benzo[d]isothiazole
hydrazones. Eur. J. Med. Chem. 2009, 44, 1801-1807.
28. Mircus, G.; Hagag, S.; Levdansky, E.; Sharon, H.; Shadkchan, Y.; Shalit, I.; Osherov, N.
Identification of novel cell wall destabilizing antifungal compounds using a conditional
Aspergillus nidulans protein kinase C mutant. J. Antimicrob. Chemother. 2009, 64, 755-763.
29. Romeiro, N.C.; Aguirre, G.; Hernandez, P.; Gonzalez, M.; Cerecetto, H.; Aldana, I.; Perez-
Silanes, S.; Monge, A.; Barreiro, E.J.; Lima, L.M. Synthesis, trypanocidal activity and docking
studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorg.
Med. Chem. 2009, 17, 641-652.
30. Cosconati, S.; Marinelli, L.; Trotta, R.; Virno, A.; Mayol, L.; Novellino, E.; Olson, A.J.;
Randazzo, A. Tandem Application of Virtual Screening and NMR Experiments in the Discovery
of Brand New DNA Quadruplex Groove Binders. J. Am. Chem. Soc. 2009, 131, 16336-16337.
31. He, L.Y.; Zhang, L.; Liu, X.F.; Li, X.H.; Zheng, M.Y.; Li, H.L.; Yu, K.Q.; Chen, K.X.; Shen, X.;
Jiang, H.L., et al., Discovering Potent Inhibitors Against the beta-Hydroxyacyl-Acyl Carrier
Protein Dehydratase (FabZ) of Helicobacter pylori: Structure-Based Design, Synthesis, Bioassay,
and Crystal Structure Determination. J. Med. Chem. 2009, 52, 2465-2481.

Molecules 2010, 15
6034
32. Patkar, C.G.; Larsen, M.; Owston, M.; Smith, J.L.; Kuhn, R.J. Identification of Inhibitors of
Yellow Fever Virus Replication Using a Replicon-Based High-Throughput Assay. Antimicrob.
Agents Chemother. 2009, 53, 4103-4114.
33. Marlo, J.E.; Niswender, C.M.; Days, E.L.; Bridges, T.M.; Xiang, Y.; Rodriguez, A.L.; Shirey,
J.K.; Brady, A.E.; Nalywajko, T.; Luo, Q., et al. Discovery and Characterization of Novel
Allosteric Potentiators of M-1 Muscarinic Receptors Reveals Multiple Modes of Activity. Mol.
Pharmacol. 2009, 75, 577-588.
34. Patel, V.; Mazitschek, R.; Coleman, B.; Nguyen, C.; Urgaonkar, S.; Cortese, J.; Barker, R.H.;
Greenberg, E.; Tang, W.P.; Bradner, J.E., et al. Identification and Characterization of Small
Molecule Inhibitors of a Class I Histone Deacetylase from Plasmodium falciparum. J. Med.
Chem. 2009, 52, 2185-2187.
35. Peterson, Q.P.; Hsu, D.C.; Goode, D.R.; Novotny, C.J.; Totten, R.K.; Hergenrother, P.J.
Procaspase-3 Activation as an Anti-Cancer Strategy: Structure-Activity Relationship of
Procaspase-Activating Compound 1 (PAC-1) and Its Cellular Co-Localization with Caspase-3. J.
Med. Chem. 2009, 52, 5721-5731.
Sample Availability: Please contact the corresponding author.
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).